CN107670103A - The bone cement and preparation method that polyethylene pyrrole network alkanone is modified - Google Patents
The bone cement and preparation method that polyethylene pyrrole network alkanone is modified Download PDFInfo
- Publication number
- CN107670103A CN107670103A CN201710835020.4A CN201710835020A CN107670103A CN 107670103 A CN107670103 A CN 107670103A CN 201710835020 A CN201710835020 A CN 201710835020A CN 107670103 A CN107670103 A CN 107670103A
- Authority
- CN
- China
- Prior art keywords
- bone cement
- liquid
- polyethylene pyrrole
- pyrrole network
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Abstract
The bone cement and preparation method being modified the present invention relates to polyethylene pyrrole network alkanone, including pulvis and solidify liquid：Pulvis is half-H 2 O calcium sulphate, and solidify liquid is the polyethylene pyrrole network alkanone aqueous solution, and concentration is 0.1%~5%, and liquid-solid ratio is 0.4~0.6ml/g.Prepare the polyethylene pyrrole network alkanone solidify liquid that concentration is 0.1%~5%；Then the mixing of half-H 2 O calcium sulphate pulvis is added according to liquid-solid ratio, stirred, cold curing forms injectable type bone cement.Because polyethylene pyrrole network alkanone is a kind of high molecular polymer for being highly soluble in water, its is odorless, tasteless, almost non-toxic, and has good biocompatibility and stronger associativity.Bone cement in the present invention also has good biocompatibility and degradability, can be used in the filling and reparation of various Cranial defects.Applied to organizational project and field of medicaments.
Description
Technical field
The present invention relates to a kind of injectable type bone cement and preparation method for human body hard tissue reparation, particularly poly- second
The bone cement and preparation method that alkene pyrrole network alkanone is modified；It is mainly used in the fields such as bio-medical material.
Background technology
Because contingency, wound or disease can cause bone damage or Cranial defect, traditional surgical operation not only hold high by expense
It is expensive, but also pain can be brought to patient.For a long time, in order to seek preferable bone grafting material, many scientific research personnel are unremitting
Effort.At present, bone grafting material is broadly divided into three major types：Autologous bone bone grafting material, allograph bone bone grafting material and people
Work bone bone grafting material.Although autologous bone can cause due to its limited amount and to itself secondary wound without immunological rejection
Evil the shortcomings of and it is restricted in clinical practice；Although allograph bone quantity is more compared with autologous bone, because it there may be
Immunological rejection, donor may have the limitation of virus and social morality ethics problem etc., so allograph bone is nor bone grafting material
Be preferably selected.In order to solve the problems, such as both the above bone grafting material, in order to obtain preferable bone grafting material, then, section
The workers of grinding begin one's study artificial bone.
Bone cement is the bone alternate material of a new generation, in fixation of the filling of Cranial defect, bone collection and bone grafting material etc.
Aspect has a wide range of applications.Bioactive bone cement is made up of solid phase and liquid phase two parts, and solid liquid phase is according to certain ratio
Can be formed after mixing with can self-curing slurry, the slurry has any formability thereof.Calcium sulfate bone cement (CSC) is repaiied as bone
Existing more than the 100 years history of multiple material, because its can self solidified in situ, there is syringeability and osteoinductive, and can drop completely
The shortcomings of the advantages that solution becomes good bone renovating material, but its bioactivity is low, degradation rate is fast constrains its again
Development and clinical practice.Therefore, calcium sulfate bone cement is improved so that it is more widely used is repaiied as bone
One of emphasis of multiple Material Field research.
Half-H 2 O calcium sulphate has the hydraulicity, run into after the aqueous solution can self solidified in situ be high intensity calcium sulphate dihydrate, two
H 2 O calcium sulphate can promote Gegenbaur's cell to adhere to, and promote skeletonization, while osteoclast can absorb calcium sulfate, achieve biology
Degraded.But in clinical practice, because the degradation rate of calcium sulfate is faster than the speed of New born formation, easily cause operative failure.
Polyethylene pyrrole network alkanone (polyvinylpyrrolidone, PVP) is a kind of high molecular polymerization for being highly soluble in water
Thing, its is odorless, tasteless, almost non-toxic, and has good biocompatibility and stronger associativity.Good biocompatibility
PVP is set to be received much concern in medicine and technical field of biological material, stronger associativity enables PVP to be combined well with other materials,
So that it has a wide range of applications.
Because the synthetic bone graft prepared by single material typically can all have intensity deficiency, degradation rate and new bone again
The shortcomings of raw speed is not consistent, therefore, the bone that the material of other Safe beneficials is prepared according to certain ratio combination is moved
Plant material material, it can be learnt from other's strong points to offset one's weaknesses, it is a kind of preferably artificial so as to obtain so as to improve the physics and chemistry of material and biology performance
Bone renovating material.
The content of the invention
The bone cement and preparation method being modified it is an object of the invention to provide a kind of new polyethylene pyrrole network alkanone, lead to
Crossing bone cement material made from this method has strong stronger anti-collapsibility, preferable syringeability and higher pressure resistance
Degree, while also there is good biocompatibility and biodegradability.
The bone cement that a kind of new polyethylene pyrrole network alkanone that the present invention uses is modified, including pulvis and solidify liquid：Its
Middle pulvis is half-H 2 O calcium sulphate, and solidify liquid is polyethylene pyrrole network alkanone (PVP) aqueous solution, and concentration is 0.1%~5%, liquid-solid ratio
For 0.4~0.6ml/g.
The preparation method for the bone cement that the polyethylene pyrrole network alkanone of the present invention is modified, comprises the following steps：
(1) polyethylene pyrrole network alkanone (PVP) solidify liquid that concentration is 0.1%~5% is proportionally prepared；
(2) mixing of half-H 2 O calcium sulphate pulvis is added according to liquid-solid ratio, be uniformly mixed, cold curing forms injectable type
Bone cement.
Described half-H 2 O calcium sulphate is the half-H 2 O calcium sulphates of α mono-.
In the present invention, half-H 2 O calcium sulphate is mixed according to certain liquid-solid ratio with the polyethylene pyrrole network alkanone aqueous solution, solidified,
Prepare a kind of new injectable type bone cement.Polyethylene pyrrole network alkanone is a kind of high molecular polymer for being highly soluble in water,
Its is odorless, tasteless, almost non-toxic, and has good biocompatibility and stronger associativity.Good biocompatibility makes
PVP receives much concern in medicine and technical field of biological material, and stronger associativity enables PVP to be combined well with other materials, institute
The mechanical property of bone cement can be improved with the addition of polyethylene pyrrole network alkanone.Meanwhile the bone cement in the present invention is also with good
Good biocompatibility and degradability, can be used in the filling and reparation of various Cranial defects.Applied to organizational project and medicine
Field.
Brief description of the drawings
Fig. 1：Injectable time diagram after injectable type bone cement material solidification.
Fig. 2：The result figure of compression strength is tested after injectable type bone cement material solidification.
Fig. 3：XRD spectrum after injectable type bone cement material solidification.
Fig. 4：The SEM figures of injectable type bone cement material.
Embodiment
Present disclosure is described in further detail with reference to embodiment：
Embodiment 1：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the polyethylene pyrrole network alkanone that the concentration for measuring 2.5mL is 0.1% is water-soluble
Liquid, it is according to the ratio mixing 0.5min that liquid-solid ratio is 0.5mL/g, injectable time by the liquid phase aqueous solution and solid phase powder
4.1min or so, as shown in Figure 1.Intensity test is carried out to bone cement sample after solidification, intensity test sample is
Cylindric (Φ 6mm × 12mm), compression strength average value are 15.15Mpa, as shown in Figure 2, and human body cancellous bone compression strength
Generally 5~10Mpa, so meeting the requirement of practical application.
Embodiment 2：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the polyethylene pyrrole network alkanone that the concentration for measuring 2.5mL is 0.5% is water-soluble
Liquid, it is according to the ratio mixing 0.5min that liquid-solid ratio is 0.5mL/g, injectable time by the liquid phase aqueous solution and solid phase powder
4.5min or so, as shown in Figure 1.Bone cement sample carries out intensity test, pressure resistance after solidifying according to embodiment 1 to it
Degree average value is 15.64Mpa, and as shown in Figure 2, and human body cancellous bone compression strength is generally 5~10Mpa, so meeting reality
The requirement of border application.By the bone cement grind into powder after solidification, material phase analysis is then carried out to it by XRD, such as the institute of accompanying drawing 3
Show, the bone cement main component after solidification is calcium sulphate dihydrate, illustrates that half-H 2 O calcium sulphate quickly becomes two water sulphur in solidification process
Sour calcium.Research shows that calcium sulphate dihydrate can promote Gegenbaur's cell to adhere to, and promotes skeletonization, while osteoclast can absorb sulphur
Sour calcium, achieves biodegradation.
Embodiment 3：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the concentration for measuring 2.5mL is the 1% polyethylene pyrrole network alkanone aqueous solution,
It is according to the ratio mixing 0.5min that liquid-solid ratio is 0.5mL/g, injectable time by the liquid phase aqueous solution and solid phase powder
4.0min or so, as shown in Figure 1.Bone cement sample carries out intensity test, pressure resistance after solidifying according to embodiment 1 to it
Degree average value is 16.43Mpa, and as shown in Figure 2, and human body cancellous bone compression strength is generally 5~10Mpa, so meeting reality
The requirement of border application.By the bone cement grind into powder after solidification, material phase analysis is then carried out to it by XRD, such as the institute of accompanying drawing 3
Show, the bone cement main component after solidification is calcium sulphate dihydrate, illustrates that half-H 2 O calcium sulphate quickly becomes two water sulphur in solidification process
Sour calcium.Then SEM signs are carried out to the powder, as shown in Figure 4, the bone cement after solidification is in the form of a column distribution.
Embodiment 4：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the concentration for measuring 2.5mL is the 3% polyethylene pyrrole network alkanone aqueous solution,
It is according to the ratio mixing 0.5min that liquid-solid ratio is 0.5mL/g, injectable time by the liquid phase aqueous solution and solid phase powder
4.03min or so, as shown in Figure 1.Bone cement sample carries out intensity test, resistance to compression after solidifying according to embodiment 1 to it
Average strength is 18.34Mpa, and as shown in Figure 2, and human body cancellous bone compression strength is generally 5~10Mpa, so meeting
The requirement of practical application.Characterized by XRD and SEM and carry out composition and morphology analysis, its main component is calcium sulphate dihydrate, in post
Shape is distributed.Bone cement is put into SBF solution after solidification and soaked, anti-collapsibility is good.When bone cement is used to be locally filled with, need straight
The fluid flow blood at Cranial defect position is contacted, good anti-collapsibility makes it be not easy to be broken up, several so as to improve the success of operation
Rate.
Embodiment 5：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the concentration for measuring 2.5mL is the 5% polyethylene pyrrole network alkanone aqueous solution,
It is according to the ratio mixing 0.5min that liquid-solid ratio is 0.5mL/g, injectable time by the liquid phase aqueous solution and solid phase powder
3.56min or so, as shown in Figure 1.Bone cement sample carries out intensity test, resistance to compression after solidifying according to embodiment 1 to it
Average strength is 19.01Mpa, and as shown in Figure 2, and human body cancellous bone compression strength is generally 5~10Mpa, so meeting
The requirement of practical application.Characterized by XRD and SEM and carry out composition and morphology analysis, its main component is calcium sulphate dihydrate, in post
Shape is distributed.Bone cement is put into SBF solution after solidification and soaked, anti-collapsibility is good.
Embodiment 6：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, measure 2.5mL deionized water, by liquid phase water and solid phase powder according to
The ratio that liquid-solid ratio is 0.5mL/g mixes 0.5min, and the injectable time is 3.81min or so.Bone cement after solidifying to it
Sample carries out intensity test, and compression strength average value is 12.57Mpa, and human body cancellous bone compression strength be generally 5~
10Mpa, so meeting the requirement of practical application.Characterizing progress composition and morphology analysis, its main component by XRD and SEM is
Calcium sulphate dihydrate, it is in the form of a column distribution.Bone cement is put into SBF solution after solidification and soaked, anti-collapsibility is good.
Embodiment 7：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the concentration for measuring 2mL is the 0.1% polyethylene pyrrole network alkanone aqueous solution,
It is according to the ratio mixing 0.5min that liquid-solid ratio is 0.4mL/g, injectable time by the liquid phase aqueous solution and solid phase powder
4.2min left and right.Bone cement sample carries out intensity test after solidifying to it, and its compression strength is higher than human body cancellous bone resistance to compression
The requirement of intensity (5~10Mpa).It is sulfate dihydrate to be characterized by XRD and SEM and carry out composition and morphology analysis, its main component
Calcium, it is in the form of a column distribution.Bone cement is put into SBF solution after solidification and soaked, anti-collapsibility is good.
Embodiment 8：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the concentration for measuring 2mL is the 3% polyethylene pyrrole network alkanone aqueous solution, will
The liquid phase aqueous solution and solid phase powder are according to the ratio mixing 0.5min that liquid-solid ratio is 0.4mL/g, injectable time
3.9min left and right.Bone cement sample carries out intensity test after solidifying to it, and its compression strength is higher than human body cancellous bone resistance to compression
The requirement of intensity (5~10Mpa).It is sulfate dihydrate to be characterized by XRD and SEM and carry out composition and morphology analysis, its main component
Calcium, it is in the form of a column distribution.Bone cement is put into SBF solution after solidification and soaked, anti-collapsibility is good.
Embodiment 9：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the concentration for measuring 2mL is the 5% polyethylene pyrrole network alkanone aqueous solution, will
The liquid phase aqueous solution and solid phase powder are according to the ratio mixing 0.5min that liquid-solid ratio is 0.4mL/g, injectable time
3.8min left and right.Bone cement sample carries out intensity test after solidifying to it, and its compression strength is higher than human body cancellous bone resistance to compression
The requirement of intensity (5~10Mpa).It is sulfate dihydrate to be characterized by XRD and SEM and carry out composition and morphology analysis, its main component
Calcium, it is in the form of a column distribution.Bone cement is put into SBF solution after solidification and soaked, anti-collapsibility is good.
Embodiment 10：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the concentration for measuring 3mL is the 0.1% polyethylene pyrrole network alkanone aqueous solution,
It is according to the ratio mixing 0.5min that liquid-solid ratio is 0.6mL/g, injectable time by the liquid phase aqueous solution and solid phase powder
5.24min left and right.Bone cement sample carries out intensity test after solidifying to it, and its compression strength is higher than human body cancellous bone resistance to compression
The requirement of intensity (5~10Mpa).It is sulfate dihydrate to be characterized by XRD and SEM and carry out composition and morphology analysis, its main component
Calcium, it is in the form of a column distribution.Bone cement is put into SBF solution after solidification and soaked, anti-collapsibility is good.
Embodiment 11：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the concentration for measuring 3mL is the 3% polyethylene pyrrole network alkanone aqueous solution, will
The liquid phase aqueous solution and solid phase powder are according to the ratio mixing 0.5min that liquid-solid ratio is 0.6mL/g, injectable time
4.42min left and right.Bone cement sample carries out intensity test after solidifying to it, and its compression strength is higher than human body cancellous bone resistance to compression
The requirement of intensity (5~10Mpa).It is sulfate dihydrate to be characterized by XRD and SEM and carry out composition and morphology analysis, its main component
Calcium, it is in the form of a column distribution.Bone cement is put into SBF solution after solidification and soaked, anti-collapsibility is good.
Embodiment 12：
At room temperature, 5g half-H 2 O calcium sulphates are weighed, the concentration for measuring 3mL is the 5% polyethylene pyrrole network alkanone aqueous solution, will
The liquid phase aqueous solution and solid phase powder are according to the ratio mixing 0.5min that liquid-solid ratio is 0.6mL/g, injectable time
4.13min left and right.Bone cement sample carries out intensity test after solidifying to it, and its compression strength is higher than human body cancellous bone resistance to compression
The requirement of intensity (5~10Mpa).It is sulfate dihydrate to be characterized by XRD and SEM and carry out composition and morphology analysis, its main component
Calcium, it is in the form of a column distribution.Bone cement is put into SBF solution after solidification and soaked, anti-collapsibility is good.
Claims (3)
1. a kind of injectable type bone cement and preparation method, including pulvis and solidify liquid：Wherein pulvis is half-H 2 O calcium sulphate, solidification
Liquid is the polyethylene pyrrole network alkanone aqueous solution, and concentration is 0.1%~5%, and liquid-solid ratio is 0.4~0.6ml/g.
2. material as claimed in claim 1, it is characterized in that the polyethylene pyrrole network that it is 0.1%~5% that the solidify liquid, which is concentration,
The alkanone aqueous solution.
3. the preparation method of injectable type bone cement material according to claim 1 or 2, comprises the following steps:
(1) the polyethylene pyrrole network alkanone solidify liquid that concentration is 0.1%~5% is proportionally prepared；
(2) mixing of half-H 2 O calcium sulphate pulvis is added according to liquid-solid ratio, be uniformly mixed, cold curing forms injectable type bone water
Mud.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710835020.4A CN107670103A (en) | 2017-09-15 | 2017-09-15 | The bone cement and preparation method that polyethylene pyrrole network alkanone is modified |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710835020.4A CN107670103A (en) | 2017-09-15 | 2017-09-15 | The bone cement and preparation method that polyethylene pyrrole network alkanone is modified |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107670103A true CN107670103A (en) | 2018-02-09 |
Family
ID=61136553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710835020.4A Pending CN107670103A (en) | 2017-09-15 | 2017-09-15 | The bone cement and preparation method that polyethylene pyrrole network alkanone is modified |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107670103A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030177A2 (en) * | 2003-09-29 | 2005-04-07 | Cipla Limited | Pharmaceutical formulation with improved stability |
| CN1844010A (en) * | 2005-04-08 | 2006-10-11 | 豪迈帝凯莱宾格股份有限公司 | Calcium phosphate cement |
| US20090074753A1 (en) * | 2004-10-14 | 2009-03-19 | Lynch Samuel E | Platelet-derived growth factor compositions and methods of use thereof |
| WO2012093979A1 (en) * | 2011-01-06 | 2012-07-12 | Mahmut Bilgic | Water-soluble dosage forms comprising ibandronate |
| US20140294913A1 (en) * | 2013-03-28 | 2014-10-02 | Nesrin Hasirci | Biodegradable bone fillers, membranes and scaffolds containing composite particles |
| CN104645418A (en) * | 2015-01-22 | 2015-05-27 | 天津大学 | Injectable bone cement and preparation method thereof |
| CN105107021A (en) * | 2015-09-09 | 2015-12-02 | 天津大学 | Injectable antibacterial bone cement and preparation method and application thereof |
| US9238047B1 (en) * | 2013-01-10 | 2016-01-19 | Maurice Valen | Fluorapatite nano-crystalline coated non-ceramic hydrophilic hydroxylapatite bone grafting compositions and methods for promoting bone regeneration |
| CN106344963A (en) * | 2016-10-19 | 2017-01-25 | 天津大学 | Graphene oxide modified bone cement and preparation method |
-
2017
- 2017-09-15 CN CN201710835020.4A patent/CN107670103A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030177A2 (en) * | 2003-09-29 | 2005-04-07 | Cipla Limited | Pharmaceutical formulation with improved stability |
| US20090074753A1 (en) * | 2004-10-14 | 2009-03-19 | Lynch Samuel E | Platelet-derived growth factor compositions and methods of use thereof |
| CN1844010A (en) * | 2005-04-08 | 2006-10-11 | 豪迈帝凯莱宾格股份有限公司 | Calcium phosphate cement |
| WO2012093979A1 (en) * | 2011-01-06 | 2012-07-12 | Mahmut Bilgic | Water-soluble dosage forms comprising ibandronate |
| US9238047B1 (en) * | 2013-01-10 | 2016-01-19 | Maurice Valen | Fluorapatite nano-crystalline coated non-ceramic hydrophilic hydroxylapatite bone grafting compositions and methods for promoting bone regeneration |
| US20140294913A1 (en) * | 2013-03-28 | 2014-10-02 | Nesrin Hasirci | Biodegradable bone fillers, membranes and scaffolds containing composite particles |
| CN104645418A (en) * | 2015-01-22 | 2015-05-27 | 天津大学 | Injectable bone cement and preparation method thereof |
| CN105107021A (en) * | 2015-09-09 | 2015-12-02 | 天津大学 | Injectable antibacterial bone cement and preparation method and application thereof |
| CN106344963A (en) * | 2016-10-19 | 2017-01-25 | 天津大学 | Graphene oxide modified bone cement and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 袁宁等: "庆大霉素和 O-羧甲基壳聚糖对硫酸钙骨水泥改性研究", 《骨与关节修复重建》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| O'neill et al. | Critical review: Injectability of calcium phosphate pastes and cements | |
| DK173634B1 (en) | Two-phase bone cement mixing | |
| Sobczak-Kupiec et al. | Synthesis and characterization of ceramic-polymer composites containing bioactive synthetic hydroxyapatite for biomedical applications | |
| Liu et al. | A novel injectable, cohesive and toughened Si-HPMC (silanized-hydroxypropyl methylcellulose) composite calcium phosphate cement for bone substitution | |
| CN103785058B (en) | Comprise the fibrin composition of strontium compound | |
| Ambrosio et al. | Injectable calcium-phosphate-based composites for skeletal bone treatments | |
| CN100425295C (en) | Premix plaster calcium phosphate bone cement | |
| CN101816808B (en) | Injectable porous high-strength bone repair material | |
| CN106344963A (en) | Graphene oxide modified bone cement and preparation method | |
| GB2483353A (en) | Method for forming bone cement | |
| Xu et al. | Bioactive tricalcium silicate/alginate composite bone cements with enhanced physicochemical properties | |
| WO2007015208A2 (en) | Injectable composite material suitable for use as a bone substitute | |
| CN104591679A (en) | Modified magnesium oxychloride bone cement as well as preparation method and application thereof | |
| CN106139253B (en) | The bone cement that the composition of composite bone cement can be formed and formed by it | |
| EP3834855A1 (en) | Pre-mixed strontium silicate-based biological hydraulic cementing paste composition, preparation method therefor, and application thereof | |
| CN106693063B (en) | A kind of anti-collapsibility calcium silicon substrate composite bone cement and its preparation method and application | |
| CN107670103A (en) | The bone cement and preparation method that polyethylene pyrrole network alkanone is modified | |
| CN110339395B (en) | PMMA-based hydrated bone cement and preparation method and application thereof | |
| KR20150054880A (en) | Bioresorbable ceramic composition for forming a three dimensional scaffold | |
| CN104645418A (en) | Injectable bone cement and preparation method thereof | |
| CN107638593A (en) | Injectable calcium sulphate cement bone cement and preparation method with biocidal property | |
| CN109562203A (en) | Phosphorus matter calcium cement composition comprising blood | |
| CN107412874B (en) | Injectable calcium sulfate hemihydrate/octacalcium phosphate/sodium hyaluronate sulfate composite artificial bone material and preparation method thereof | |
| CN109260523A (en) | A kind of calcium phosphate bone cement complex microsphere and its preparation method and application | |
| Lei et al. | Mechanical properties of calcium sulphate/hydroxyapatite cement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180209 |